Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome
eLife · 03.01.2023 · 12
DOI: 10.7554/elife.81892 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 03.01.2023. Verfasst von Dongwon Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Baylor College of Medicine, Houston, United States. Hauptthemen laut MEDLINE: Angelman Syndrome. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIMH NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
UBE3A encodes ubiquitin protein ligase E3A, and in neurons its expression from the paternal allele is repressed by the UBE3A antisense transcript ( UBE3A-ATS ). This leaves neurons susceptible to loss-of-function of maternal UBE3A . Indeed, Angelman syndrome, a severe neurodevelopmental disorder, is caused by maternal UBE3A deficiency. A promising therapeutic approach to treating Angelman syndrome is to reactivate the intact paternal UBE3A by suppressing UBE3A-ATS . Prior studies show that many neurological phenotypes of maternal Ube3a knockout mice can only be rescued by reinstating Ube3a expression in early development, indicating a restricted therapeutic window for Angelman syndrome. Here, we report that reducing Ube3a-ATS by antisense oligonucleotides in juvenile or adult maternal Ube3a knockout mice rescues the abnormal electroencephalogram (EEG) rhythms and sleep disturbance, two prominent clinical features of Angelman syndrome. Importantly, the degree of phenotypic improvement correlates with the increase of Ube3a protein levels. These results indicate that the therapeutic window of genetic therapies for Angelman syndrome is broader than previously thought, and EEG power spectrum and sleep architecture should be used to evaluate the clinical efficacy of therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Baylor College of Medicine, Houston, United States.
- The Cain Foundation Laboratories, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, United States.
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States.
- Ionis Pharmaceuticals, Carlsbad, United States.
- Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, United States.
ORCID-Profile: Wu Chen, Armando Rivera, Mingshan Xue
Förderung
- NINDS NIH HHS
- NIMH NIH HHS
- NCI NIH HHS
- NICHD NIH HHS
- Texas Children's Hospital
- National Institute of Neurological Disorders and Stroke
- National Institute of Mental Health
Zitieren
APA
Lee, D., Chen, W., Kaku, H. N., Zhuo, X., Chao, E. S., Soriano, A., Kuncheria, A., Flores, S., Kim, J. H., Rivera, A., Rigo, F., Jafar-Nejad, P., Beaudet, A. L., Caudill, M. S., & Xue, M. (2023). Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome. eLife, 12. https://doi.org/10.7554/elife.81892
Vancouver
Lee D, Chen W, Kaku HN, Zhuo X, Chao ES, Soriano A, et al. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome. eLife. 2023;12. doi:10.7554/elife.81892
BibTeX
@article{Lee2023,
author = {Lee, Dongwon and Chen, Wu and Kaku, Heet Naresh and Zhuo, Xinming and Chao, Eugene S and Soriano, Armand and Kuncheria, Allen and Flores, Stephanie and Kim, Joo Hyun and Rivera, Armando and Rigo, Frank and Jafar-Nejad, Paymaan and Beaudet, Arthur L and Caudill, Matthew S and Xue, Mingshan},
title = {Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.81892}
}
EUVIMED